124620-51-5

Basic information

• Product Name: L-Norvaline, 5-hydroxy-N- [(phenylmethoxy)carbonyl]-, 1,1-dimethylethylester
• Synonyms: L-Norvaline, 5-hydroxy-N- [(phenylmethoxy)carbonyl]-, 1,1-dimethylethylester;(S)-tert-butyl 2-(benzyloxycarbonylamino)-5-hydroxypentanoate;N-benzoxycarbonyl-5-hydroxy-L-norvaline, iso-proryl ester;5-Hydroxy-N-[(phenylmethoxy)carbonyl]-L-norvaline tert-butyl ester;tert-Butyl (S)-2-(benzyloxycarbonylamino)-5-hydroxypentanoate
• CAS NO: 124620-51-5
• Molecular Formula: C₁₇H₂₅NO₅
• Molecular Weight: 323.3841
• Mol File: 124620-51-5.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 475.67 °C at 760 mmHg
• Flash Point: 241.477 °C
• Appearance: /
• Density: 1.136
• Refractive Index: 1.517
• Storage Temp.: 2-8°C
• CAS DataBase Reference: L-Norvaline, 5-hydroxy-N- [(phenylmethoxy)carbonyl]-, 1,1-dimethylethylester(CAS DataBase Reference)
• NIST Chemistry Reference: L-Norvaline, 5-hydroxy-N- [(phenylmethoxy)carbonyl]-, 1,1-dimethylethylester(124620-51-5)
• EPA Substance Registry System: L-Norvaline, 5-hydroxy-N- [(phenylmethoxy)carbonyl]-, 1,1-dimethylethylester(124620-51-5)

Safety Data

• Hazardous Substances Data: 124620-51-5(Hazardous Substances Data)

Usage

General Description

L-Norvaline, 5-hydroxy-N-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethylester is a chemical compound with potential biological and pharmacological properties. L-Norvaline is an amino acid derivative that has been studied for its potential to increase muscle mass and improve athletic performance. The 5-hydroxy-N-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethylester group is a specific chemical structure that may contribute to the compound's bioactivity. L-Norvaline, 5-hydroxy-N- [(phenylmethoxy)carbonyl]-, 1,1-dimethylethylester may have applications in the development of novel pharmaceuticals or supplements targeting muscle growth and physical performance. Further research is needed to fully understand the potential benefits and risks associated with this chemical compound.

InChI:InChI=1/C17H25NO5/c1-17(2,3)23-15(20)14(10-7-11-19)18-16(21)22-12-13-8-5-4-6-9-13/h4-6,8-9,14,19H,7,10-12H2,1-3H3,(H,18,21)/t14-/m0/s1

Upstream product

• 540-88-5 acetic acid tert-butyl ester 
• 81470-51-1 tert-butyl N-benzyloxycarbonyl-L-pyroglutamate 
• 57732-63-5 1-tert-butyl 5-methyl (2S)-2-{[(benzyloxy)carbonyl]amino}pentanedioate 
• 4652-65-7 (S)-2-Benzyloxycarbonylamino-pentanedioic acid 5-methyl ester 
• 3077-51-8 γ-methyl L-glutamate hydrochloride 
• 56-86-0 L-glutamic acid 
• 1155-62-0 N-benzyloxycarbonyl-L-glutamic acid 
• 5891-45-2 (S)-2-(benzyloxycarbonylamino)pentanedioic acid tert-butyl ester 
• 501-53-1 benzyl chloroformate 
• 5891-45-2 N-benzoyloxycarbonyl L-glutamic acid α-t-butylester 
• 35418-16-7 L-t-butyl pyroglutamate 
• 4124-76-9 N-(benzyloxycarbonyl)-L-glutamic acid anhydride 
• 32159-21-0 Cbz-L-pGlu-OH 

Downstream Products

• 89969-29-9 N⁵-acetyl-N⁵-(benzyloxy)-N²-(benzyloxycarbonyl)-L-ornithine 
• 124620-53-7 allyl N⁵-acetyl-N⁵-(benzyloxy)-N²-(benzyloxycarbonyl)-L-ornithinate 
• 92412-96-9 N⁵-acetyl-N⁵-(benzyloxy)-N²-(benzyloxycarbonyl)-L-ornithine 1-tert-butyl ester 
• 124620-55-9 N⁵-acetyl-N⁵-(benzyloxy)-N²-(benzyloxycarbonyl)-L-ornithyl-N⁵-acetyl-N⁵-(benzyloxy)-L-ornithine 
• 124620-54-8 allyl N⁵-acetyl-N⁵-(benzyloxy)-N²-(benzyloxycarbonyl)-L-ornithyl-N⁵-acetyl-N⁵-(benzyloxy)-L-ornithinate 
• 124620-56-0 (N⁵-acetyl-N⁵-(benzyloxy)-N²-(benzyloxycarbonyl)-L-ornithyl)-(N⁵-acetyl-N⁵-(benzyloxy)-L-ornithyl)-N⁵-acetyl-N⁵-(benzyloxy)-L-ornithine 
• 124650-79-9 Allyl N⁵-acetyl-N⁵-(benzyloxy)-N²-(benzyloxycarbonyl)-L-ornithyl-N⁵-acetyl-N⁵-(benzyloxy)-L-ornithyl-N⁵-acetyl-N⁵-(benzyloxy)-L-ornithinate 
• 130761-77-2 N⁵-acetyl-N⁵-(benzyloxy)-N²-(benzyloxycarbonyl)-L-ornithyl-N⁵-acetyl-N⁵-(benzyloxy)-L-ornithyl-N⁵-acetyl-N⁵-(benzyloxy)-L-ornithyl-L-seryl-1,4-dibenzyl-D-aspartate 
• 130761-70-5 N²-(3,5-dinitrobenzoyl)-5-hydroxy-L-norvaline 1-tert-butyl ester 
• 130761-72-7 benzyl N⁵-acetyl-N⁵-(benzyloxy)-N²-(benzyloxycarbonyl)-L-ornithinate 
• 130761-71-6 allyl N²-(3,5-dinitrobenzoyl)-N⁵-acetyl-N⁵-(benzyloxy)-L-ornithinate 
• 130761-84-1 N⁵-acetyl-N⁵-hydroxy-L-ornithyl-N⁵-acetyl-N⁵-hydroxy-L-ornithyl-N⁵-acetyl-N⁵-hydroxy-L-ornithyl-D-4-hydroxyphenylglycine 
• 130761-74-9 benzyl N⁵-acetyl-N⁵-(benzyloxy)-N²-(benzyloxycarbonyl)-L-ornithyl-N⁵-acetyl-N⁵-(benzyloxy)-L-ornithyl-N⁵-acetyl-N⁵-(benzyloxy)-L-ornithyl-L-serinate 
• 130761-82-9 benzyl N⁵-acetyl-N⁵-(benzyloxy)-N²-(benzyloxycarbonyl)-L-ornithyl-N⁵-acetyl-N⁵-(benzyloxy)-L-ornithyl-N⁵-acetyl-N⁵-(benzyloxy)-L-ornithyl-D-4-hydroxyphenylglycinate 

Relevant articles and documents

PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES

Compounds of Formula (I) a or (I) b: including certain quinone derivatives, and the corresponding pharmaceutical compositions, which may serve to modulate ferroptosis in a subject. Also disclosed herein are the preparations of these compounds and pharmaceutical compositions and their potential uses in the manufacture of a medicament in reducing reactive oxygen species (ROS) in a cell and for preventing, treating, ameliorating certain related disorder or a disease.

DIAZABICYCLO[4.3.1]DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS

The present invention relates to diazabicyclo[4.3.1]decane derivatives, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said diazabicyclo[4.3.1]decane derivatives can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.

Diazabicyclo[4.3.1]decane derivatives for treatment of psychiatric disorders

The present invention relates to diazabicyclo[4.3.1]decane derivatives of formula (I), pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said diazabicyclo[4.3.1]decane derivatives are inhibitors of the FK506 binding protein (FKBP's) and can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.